Paracetamol Baxter Holding (Paracetamol)

Paracetamol works by inhibiting cyclooxygenase enzymes in the central nervous system, which reduces the synthesis of prostaglandins that mediate pain and regulate body temperature. This central action provides analgesic and antipyretic effects without significant peripheral anti‑inflammatory activity.

The specific dose of Paracetamol Baxter Holding is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and overall health status. Healthcare professionals follow local guidelines and product labeling to calculate the appropriate infusion volume and rate for each individual.

Paracetamol Baxter Holding falls under an unknown pregnancy category, and safety data for intravenous use during pregnancy or lactation are limited. Caution is advised, and the product should only be used if the potential benefit justifies any possible risk to the fetus or infant, after consulting a healthcare professional.

To order Paracetamol Baxter Holding, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and the necessary import documentation.

The primary alternative to intravenous paracetamol is intravenous ibuprofen, which adds anti‑inflammatory activity but carries a higher risk of gastrointestinal and renal side effects. Paracetamol offers a more favorable safety profile for hepatic and renal function when used at recommended doses, making it a preferred choice for patients where anti‑inflammatory effects are not required.

Paracetamol Baxter Holding should be stored at 2‑8 °C in a refrigerator, protected from light. The container must not be frozen or shaken. Prior to use, inspect the solution for particulate matter or discoloration, and handle it using aseptic techniques to maintain sterility.

Paracetamol Baxter Holding is administered intravenously by slow infusion, typically over 15 minutes, using a calibrated infusion set. The exact infusion rate and total volume are prescribed by the treating clinician, who also monitors the patient for any immediate adverse reactions during and after administration.

The most serious risks include acute liver failure, especially in cases of overdose or when combined with other hepatotoxic agents, and severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome. Rapid infusion can also cause hypotension, and rare blood disorders like agranulocytosis have been reported.

Paracetamol Baxter Holding should be avoided in patients with known severe hepatic impairment, a history of hypersensitivity to paracetamol or any component of the formulation, and in those who have experienced serious adverse reactions to previous paracetamol therapy. Caution is also warranted for patients with uncontrolled severe renal disease.